NCT01326702 - Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Adult B Acute Lymphoblastic LeukemiaAdult Nasal Type Extranodal NK/T-Cell LymphomaAdult Solid NeoplasmAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaChronic Lymphocytic LeukemiaCutaneous B-Cell Non-Hodgkin LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueHepatosplenic T-Cell LymphomaIntraocular LymphomaLymphomatous Involvement of Non-Cutaneous Extranodal SiteMature T-Cell and NK-Cell Non-Hodgkin LymphomaNodal Marginal Zone LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-Cell Leukemia/LymphomaRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides and Sezary SyndromeRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRefractory Plasma Cell MyelomaSmall Intestinal LymphomaSplenic Marginal Zone LymphomaTesticular LymphomaWaldenstrom Macroglobulinemia

Interventions

DRUG

Bendamustine Hydrochloride

Given IV

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Rituximab

Given IV

DRUG

Veliparib

Given PO

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH